Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

GlaxoSmithKline Consumer - 3QFY17 Result Update - Weak Demand Accentuated by Demonetization - Reliance Securities

Posted On: 2017-02-16 21:50:44

GlaxoSmithKline Consumer Healthcare (GSK Consumer) has delivered a weak performance in 3QFY17. Its net sales fell by 11.7% to Rs8.2bn, while net profit decreased 8.3% YoY to Rs1.4bn. Marred by demonetization and weak consumer demand environment, its volumes in the core HFD segment fell by 17% in the quarter.

Trimming down our earnings estimate by 7% for FY18E in the wake of poor quarterly performance, we expect GSK Consumer to post modest revenue and earnings CAGR of 2.9% and 6% respectively through FY16-18E. However, considering the Company's market leadership, strong brands and comfortable valuations, we maintain our BUY recommendation on the stock with revised Target Price of Rs5916, which implies an upside of 16% from current levels.

Demonetisation Drags Growth

Overall quarterly volumes declined by 17% YoY, which is attributable to rippling effects of demonetization as the HFD category being discretionary in nature has a higher ticket size compared to conventional FMCG products. Close to half of GSK Consumers' sales come from rural and wholesale channel, which were significant impacted by liquidity crunch post demonetization. The Company supported the trade channels by extending credit and reducing inventory to tide over the crisis situation.

Lower A&P Aid Margins

The Company has largely been able to maintain its overall market shares of ~70%. While Horlicks and its variants have gained market share, Boost has witnessed marginal fall in the same period. Gross margins declined by 110bps YoY to 66.3%, mainly due to higher salience of sachets and commodity inflation. While employee cost remained flat at 13% of sales, A&P spends declined by 220bps YoY to 11.2% of sales. Resultant EBITDA margins rose marginally by 20bps YoY to 15.7%.

Outlook & Valuation

Although, GSK Consumer has had a rough ride in the past two years, we believe that it could recover, going forward on the back of its market leadership, strong brands, increased salience of sachets, improved penetration in North & East and higher pricing power. We expect GSK Consumer to post revenues of Rs39.4bn and Rs43.5bn and net profit of Rs6.9bn and Rs7.6bn in FY17E and FY18E, respectively. Based on expected EPS of Rs180.9, the stock currently trades at 28.2x FY18E earnings. We maintain our BUY recommendation on the stock with revised Target Price of Rs5916, based on 30x Dec-18 EPS.

Shares of GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD. was last trading in BSE at Rs.5118 as compared to the previous close of Rs. 5115.3. The total number of shares traded during the day was 350 in over 128 trades.

The stock hit an intraday high of Rs. 5118.35 and intraday low of 5035. The net turnover during the day was Rs. 1775489.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Company Visit Note: Huhtamaki PPL Ltd (HPPL) - NOT RATED - Kotak
Company Update: Shipping Corporation of India - BUY - TP Rs.110 - Kotak
IT Industry to grow at 8-9% in FY2018; Nasscom: Angel Broking
Lupin - USFDA update: Angel Broking
Company Visit Note: The Mandhana Retail Ventures Ltd - NOT RATED - Kotak
Banks : Offers protection in adverse conditions - A deeper study into Pradhan Mantri Fasal Bima Yojana - Agriculture Insurance scheme - Kotak
Energy - downstream PSUs: When the tide turns - Kotak
Company Update: Mahindra and Mahindra (M&M) - BUY - TP Rs.1565 - Kotak
Maharashtra government removes cap on taxi / auto licenses: Angel Broking
IPCA Labs - USFDA update: Angel Broking
Company Update: Gujarat State Petronet Ltd (GSPL) - ACCUMULATE - TP Rs.182 - Kotak
Management Meet Update - Zensar Technologies - CSEC Research
Company Update: VRL Logistics Ltd - BUY - TP Rs.375 - Kotak
Strategy: The impossible trinity of farm income - Kotak
Banks : Private banks accelerate gains on CASA : Deeper study into deposit profile of banks for FY2016 - Kotak
Company Update: Blue Star - ACCUMULATE - TP Rs.684 - Kotak
Banking : RBI gets into action - Kotak
Dr Reddy's - EIR for its Miryalaguda API plant: Angel Broking
Eris Lifesciences Limited - IPO Note - Angel Broking
Banks: Maharashtra announces farm loan waiver - Kotak
Company Update: Petronet LNG - ACCUMULATE - TP Rs.462 - Kotak
Company Update: Mirza International - REDUCE - TP Rs.161 - Kotak
Fiem Industries - BUY - TP Rs.1,254 - Kotak
Insurance: ICICI Prudential Life boosts industry growth - Kotak
Tejas Networks - A destination for high speed technology: Angel Broking
Hindalo Industries - Result Update - Strong show becoming a routine, maintain Buy - Centrum
Star Cement - Result Update - Profitability rebounds on better pricing, cost reduction - Centrum
FIEM Industries - Result Update - Negatives priced in, Well poised to gain in the long term - Centrum
Birla Corporation - Strong Q4 FY17; acquisition reporting strong numbers; Buy - Anand Rathi
Escorts Ltd - Ready for next leg - PhillipCapital
Earnings Update - Talwalkars Better Value Fitness (TBVF IN) - Results on expected line - CSEC Research
Result Update: Adani Port and Special Economic Zone (APZ) - BUY - TP Rs.425 - Kotak
Telecom: Two quarters of Jio - assessing the impact - Kotak
Earnings Update - Balkrishna Industries (BIL IN) - Strong volume growth continues - CSEC Research
Earnings Update - Kaveri Seeds Ltd(KSCL IN) - Muted performance - CSEC Research
Earnings Update - TTK Prestige (TTKPT IN) - Results in-line with expectation - CSEC Research
Earnings Update - Berger Paints (BRGR IN) - Results in-line with expectation - CSEC Research
Mayur Uniquoters - Footwear segment dragged performance; Maintain Hold - Awanish Chandra and Vikas Rajpal - Centrum
Ramco Cements - On solid footing; reiterate Buy - Rajesh Kumar Ravi and Vinay Menon - Centrum
Cadila gets US FDA approval for Mesalamine tablets: Angel Broking
Consumer Products: 4QFY17 review: better, but not quite there yet - Kotak
Earnings Update - MAHINDRA & MAHINDRA (MM IN) - Healthy performance led by FES - CSEC Research
Earnings Update -ITC (ITC IN) - Decent performance - CSEC Research
Earnings Update - Heidelberg Cements (HEIM IN) - Strong volumes; drive the earnings growth - CSEC Research
Cement: Cooling off - Kotak
Cadila Healthcare - 4QFY2017 Result Update - Angel Broking
Result Update: Moil - BUY - TP Rs.410 - Kotak
Result Update: Time Technoplast Ltd (TTL) - BUY - TP Rs.178 - Kotak
Earnings Update - Adani ports & SEZ (ADSEZ IN) - Healthy volume growth - CSEC Research
Pharma Update - Worst phase possibly behind us: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017